0. Reorganisation of the Commission
services
The Chairman, Prof. Kemper informed the
committee about the decisions taken during the
first formal meeting of the new Commission in
order to implement the changes to the
structure of the Commission services announced
by the President of the Commission, Romano
Prodi, in July.
He mentioned that Mr. Reichenbach has been
appointed Director General of the Personnel
and Administration Directorate-General and Mr.
Coleman as Director General of the Health and
Consumer Protection as from 1st October 1999.
Prof. Kemper said he does not see any change
in the near future in relation to the working
of the Scientific Committees.
1. Adoption of the Agenda (doc. n° SCCNFP/0216/99)
(Annex 1)
The agenda was adopted subject to the
insertion of a report on work going on in DG
III concerning guidance for SME in relation to
alternative/in-vitro methods.
2. Approval of the minutes of the 8th
plenary meeting of 23 June 1999
doc. n° SCCNFP/0204/99
The minutes were adopted subject to the
following remarks :
* Alternative methods : to the question on how
one could ensure that the alternative methods
adopted by the SCCNFP, are effectively used
and inserted in the safety dossier, the co-ordinator,
Prof. Loprieno, replied that it is up to the
SCCNFP to require that these alternative
methods are used for its designed
toxicological end-point and no longer the
traditional in-vivo studies.
* Updating Notes of Guidance : to the question
why there was no trace in the minutes
concerning the revision of Annex 5 -Margin of
Safety of Preservatives of the Notes of
Guidance, the co-ordinator replied that new
data on the exposure to preservatives were
received from COLIPA. The data will be
evaluated and the Annex might be adapted
accordingly.
* Ketoconazole : it was stated to mention
expressively in the minutes that the SCCNFP
required a follow-up to this opinion, namely
also other scientific committees (e.g. the SC
on Toxicology, Eco-toxicology and Environment,
the SC on Veterinary Measures relating to
Public Health, the SC on Medicinal Products
and Medical Devices) should consider this
chemical because of its use in other sectors
and because of its possible ecological
effects. The Chairman said he will write a
letter to the chairman of the Scientific
Steering Committee requesting the insertion of
this point in the agenda of the next SSC
meeting.
3. SCCNFP - Specific Working Parties
3.1 Alternatives
Report of the Co-ordinator
In his report of the co-ordinator, Prof.
Loprieno, presented the on-going work, and in
particular :
* the elaboration of new annexes on the
physical, chemical and microbiological
specifications of cosmetic products. To this
end, ISO and the Council of Europe will be
addressed in relation to methods, limits and
specifications for cosmetic products.
* some kind of guidance would be welcomed on
the way to behave in relation to alternative
methods found in the scientific literature or
developed by other bodies e.g. ICCVAM in the
USA. As an example, it was discussed whether
the SCCNFP can adopt an opinion on the
applicability to cosmetics products of a
particular alternative method not yet
validated by ECVAM/ESAC, e.g. the Murine Local
Lymph Node Assay, a test method for assessing
the allergic contact dermatitis potential of
chemicals/compounds.
* eye irritation : the Working Party will
resume their work on the issue once the data
from industry are received.
3.2 Hair Dyes
Report of the Co-ordinator
In his report, Prof. Andersen said he could be
very brief as no meetings were held since the
plenary meeting of 23.6.99.
Two further Working Party meetings were
scheduled to finalise the draft opinions on
the priority files identified earlier.
3.3 Inventory
Report of the Co-ordinator
In his report, the co-ordinator, Prof. Parra,
said that all the issues raised during the
last years in relation to the 1st update of
the inventory and common nomenclature have
been discussed with and accepted by the
parties concerned, namely COLIPA and the
Working Party 'Inventory' of the SCCNFP.
In view of an urgent publication, a time table
for the edition of this 1st update was
proposed and approved, which should lead to an
official adoption of the 1st update by the
SCCNFP within the next 4 months.
On the question whether it was possible to
publish the document on the internet
immediately after its adoption by the SCCNFP,
the representative of DG III said that it was
legally not possible. All community languages
must be available prior to its official
publication. However, it could be put on the
web as an working document adopted by the
SCCNFP. It was agreed to proceed this way.
3.4 Preservatives, Colorants & Fragrances
Report of the Co-ordinator
Dr. White reported on the pending issues, and
in particular on the safety assessment of
Methyleugenol, the Alpha-Hydroxy-Acids and the
polycyclic musk's.
Draft opinions were prepared and presented on
:
Acrylamide residues in cosmetic, doc. n°
SCCNFP/011/98
Acrylamide polymers are used in some cosmetic
products due to their ability to function in
many different ways. Polyacrylamides contain
traces of unreacted acrylamide.
Acrylamide is a genotoxic carcinogen and
because of residual acrylamide in
polyacrylamide preparations, lifelong use of
cosmetic products containing polyacrylamide
may represent an unacceptable high lifetime
risk of cancer.
In order that a lifetime use of cosmetics
containing polyacrylamide should not pose a
significant cancer risk, the SCCNFP was of the
opinion that the theoretical content of
residual acrylamide [calculated from the
amount of polyacrylamide added to the product
and the content of acrylamide in the
polyacrylamide used] should be <0.1 ppm in
body care leave-on products and <0.5 ppm in
other cosmetic products.
This opinion was adopted by the plenary.
Nitro Musk's - Musk Ketone, doc. n° SCCNFP/0162/99,
revision 4
- Musk Xylene, doc. n° SCCNFP/0163/99,
revision 4
Dr. White introduced the issue and said that,
although there are different routes of
exposure and therefore the overall exposure to
these chemicals should be assessed, the
Working Party stated that these draft opinions
answer only the questions asked to the SCCNFP
(mandate), namely the risk associated to the
presence of musk's in cosmetic formulations.
He also mentioned that the documents tabled
were slightly different from the one's
approved by the Working Party on 20-21.9.99.
The modification were marked with arrows or
were in italics.
The rapporteur(s) presented the document and
said that the safety assessments were made
based on the data presently available on Musk
Ketone and Xylene respectively. The subsequent
discussion focussed mainly of the proposed
maximum concentration of 1.5% of these musk's
in the fragrance compounds used in cosmetic
products. However, as the percentage of
fragrance compound in cosmetic products might
be easily changed, the proposal was not seen
as the right way to restrict the use of these
musk's.
There was concern about carcinogenicity, which
is uncertain, and on the accumulation in
mother's milk, which is uncertain as well.
These concerns should be clearly specified in
the opinions especially since the Margin of
Safety is high.
Moreover, the sensitisation data were
considered to be unsatisfactory, especially as
Musk Xylene is a potential sensitiser.
As a result, the co-ordinator invited all
members to go through the document and to
respond, by e-mail, within 2 weeks with any
question regarding information they would like
to see or any points for clarification they
would like to raise.
These comments will be sent to the rapporteurs
for consideration/inclusion in the draft
opinion and subsequent discussion in the next
Working Party meeting.
The representative of DG III stipulated that
the committee should propose a maximum
concentration in the finished product. The
directive regulates finished cosmetic
products, not its constituents, which is in
this particular case the fragrance compound.
Draft Pre-opinion concerning fragrance allergy
in consumers, doc. n° SCCNFP/0017/98
Further to the adoption during the 8th Plenary
meeting of 23.6.99 of an interim position on
fragrance allergens, the WP prepared a draft
pre-opinion as a review of the problem of
fragrance allergy in consumers due to the
presence of fragrance compounds in cosmetic
products.
The document is an analysis of the need for
appropriate consumer information and an
identification of consumer allergens.
It had been agreed that the draft pre-opinion
should be placed onto the internet with an
invitation for comments. These comments were
to be assessed by the rapporteur and chairman
before being presented to the next WP. A final
draft of the document would then be presented
to the Plenary for formal adoption as an
opinion of the SCCNFP.
The plenary meeting approved the document and
requested the Commission to put it on the
internet and to invite interested parties for
their comments before 2 November 1999.
3.5 UV Filters
Report of the Co-ordinator
Although no further Working Party meetings
have taken place since the previous plenary
meeting of 23.6.99, the co-ordinator, Dr Lina
reported on the state of the pending issues :
* S75 : Coated Titanium dioxide : a letter was
sent in July 99 requiring industry to respond
specifically to the questions asked. Industry
replied they will respond to each of the
questions asked as soon as possible. Work will
resume upon receipt of the data.
* S16 : 4-Isopropylbenzyl salicylate : further
to a mandate from DG III concerning its use as
a UV-absorber in order to protect cosmetic
products, a letter was sent to industry
requesting additional data. Also for this
issue, work will resume upon receipt of the
data.
The representative of DG III mentioned that a
joint interagency group (Commission + FDA)
will be set up to consider UVA and high SPF
claims as well as to align on SPF methodology.
This work would certainly involve the SCCNFP.
4. Report of the Chairman
In his report the Chairman, Prof. Kemper
reported on :
* + marked preservatives (Annex VI) : industry
replied saying they are identifying those
preservatives for which there is a current
interest for other uses than those laid down
in Annex VI and that they have initiated a
survey among its members on the substances
concerned.
* quenching phenomena : it was proposed to
invite Dr. D. Basketter for the next plenary
meeting of 8 December 1999 for a presentation
on the issue.
* Council of Europe : the Commission forwarded
to the members of the SCCNFP in August 99 the
working documents received from the Council of
Europe Committee of Experts on Cosmetic
Products. The Chairman said that contacts
between the Commission and the Council of
Europe have been established in order to align
their priority/policies so that duplication of
work could be avoided.
* Potential modification to entry 416 of Annex
II : the committee was mandated to evaluate
the risk of amino acids from human hair
hydrolysates with regard to the transmission
of Creutzfeldt Jakob Disease and viral
diseases. The file was addressed to the WP
'Hair Dyes' for evaluation.
* Updating of the 5FP Quality of Life Working
Programme : the point was mentioned for
information only. Researches are still invited
to submit proposals on research needs
expressed in the opinions of the committee.
5. Any Other Business
* Guidance for SME's in relation to in-vitro
methods : upon initiative of DG III, meetings
were organised with interested parties
(Commission services, representatives of
industry) to draft guidance for SME's
concerning alternative methods. The matter was
raised in order to clarify the position of the
SCCNFP in this respect.
Attendance List
Present : Mr K.E. Andersen, Mr R. Anton, Mr
J-F. Doré, Mr V. Kapoulas, Mr F. Kemper, Mr B.
Lina, Mr N. Loprieno, Mr J. Parra Mrs V.
Rogiers, Mr T. Sanner, Mr J. Vives Rego, Mr I.
White
Mrs J.D. Johansen external expert, Mr Ph.
Masson external expert, Mr D. O'Mahony
external expert, Mrs R. Schumann external
expert
Commission : Mr L. Bansil DG III, Mrs L.
Benali DG XXIV, Mrs S. Clarke DG XXIV, Mr J.
Crespo-Arce DG XXIV, Mrs M. de Solà DG XXIV,
Mrs F. Drion DG XXIV Mr G. Fracchia DG XXIV,
Mr A. Van Elst DG XXIV
Apologies : Mr P. Blain, Mr P. Elsner
Annex 1 - Scientific Committee on Cosmetic
and Non-Food Products
Agenda for the 9th plenary meeting (Brussels,
30 September 1999)
1. Adoption of the agenda - SCCNFP/0216/99
2. Approval of the minutes of the 8th plenary
meeting of 23.6.99 - SCCNFP/0204/99
3. SCCNFP - Specific Working Parties
3.1 Alternatives
Report of the Co-ordinator
Notes of Guidance :
* Elaboration of new annexes on Physical,
Chemical and Microbiological Specifications of
Cosmetic Products - SCCNFP/0208/99
* COLIPA Comments on Annex 7 - microbiological
quality of the finished cosmetic product -
SCCNFP/0175/99
3.2 Hair Dyes
Report of the Co-ordinator
* Work programme on pending files
3.3 Inventory
Report of the Co-ordinator
* Position paper : Time table for the edition
of the first update of the cosmetics inventory
- SCCNFP/0217/99
3.4 Preservatives, Colorants and Fragrances
Report of the Co-ordinator
* Draft opinion on Acrylamide - SCCNFP/0011/98
* Draft opinion on Musk Ketone - SCCNFP/0163/99
* Draft opinion on Musk Xylene - SCCNFP/0162/99
* Fragrance Allergens - SCCNFP/0017/98
3.5 UV Filters
Report of the Co-ordinator
4. Report of the Chairman
* COLIPA submission on Cells, tissues or
products of human origin. Amino acids from
human hair hydrolysate.
* Updating of the 5th FP Quality of Life
Working programme, request for proposals
* Council of Europe, Committee of Experts on
Cosmetic Products
5. Any other business
* Report on guidance for SME's in relation to
in vitro methods